AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards
AEON Biopharma announced it received an additional notice from NYSE American indicating non-compliance with an additional listing standard due to stockholders' equity deficit and continued losses. Although this does not immediately impact its listing or previously established compliance plan, failure to regain compliance by August 3, 2026, could le…